MFDS vs FDA 510(k): Which Pathway Is Faster for Class II Devices?
Direct comparison of MFDS Korea Class II registration and FDA 510(k) for foreign manufacturers — timelines, evidence requirements, fees, and strategic considerations.
The Quick Answer
For typical Class II devices, regulatory clock alone makes MFDS faster. Including KGMP and KLH setup, FDA 510(k) often completes first because KGMP requires foreign-site inspection that MFDS schedules months in advance.
Side-by-Side Comparison
| Aspect | MFDS (Korea) | FDA 510(k) (USA) |
|---|---|---|
| Review timeline | 60–90 days | 90–120 days (median 177 days incl. holds, per FDA 2024 data) |
| Predicate device required | No | Yes |
| Manufacturing site inspection | KGMP required (4–6 months) | QSR inspection not required pre-clearance |
| Local representative required | Yes (Korea License Holder) | Yes (US Agent) |
| QMS standard | KGMP | 21 CFR Part 820 / QSR |
| Clinical evidence | Substantial equivalence + Korea context | Substantial equivalence to predicate |
| Official fees (Class II) | ₩4M–₩8M ($3K–$6K) | $24,335 (FY2025 standard) |
| Total program cost (foreign manufacturer) | $30K–$80K | $30K–$100K |
| End-to-end realistic timeline | 4–9 months | 6–12 months |
| Labeling language | Korean (mandatory) | English |
| Annual maintenance | License renewal (3-year), KLH fees | Annual establishment registration |
Where MFDS Wins
1. No Predicate Device Required
FDA 510(k) requires identifying a legally marketed predicate device with substantially equivalent intended use and technological characteristics. For novel Class II devices, finding a predicate can require 6–12 weeks of regulatory strategy work.
MFDS evaluates against the Korean Medical Device Classification Code and approved-device benchmarks without a single predicate requirement. This benefits:
- AI/ML SaMD without clear FDA predicates
- Devices with novel sensor configurations
- Combination devices that span FDA classification categories
2. Faster Review Clock
MFDS internal review averages 60–90 days for Class II. FDA 510(k) Median Decision Time was 177 calendar days in FY2024 (per FDA performance report), inclusive of Refuse-to-Accept and Additional Information holds.
3. Lower Official Fees
MFDS Class II official fees range $3K–$6K. FDA 510(k) standard user fee was $24,335 in FY2025 — a 4–8x difference in government fees alone.
Where FDA Wins
1. No Pre-Clearance Manufacturing Inspection
FDA does not require QSR inspection before 510(k) clearance. KGMP inspection for MFDS often delays Korean market entry by 4–6 months beyond the regulatory review clock.
2. Larger and More Predictable Market
US medical device market is ~$190B annually (2024); Korea is ~$11B. ROI on US clearance is typically 5–10x higher for the same submission cost.
3. Broader International Recognition
FDA 510(k) clearance carries reciprocal weight with regulators in Mexico, Brazil, Saudi Arabia, and others. MFDS approval is recognized primarily within Korea (with some leverage in some ASEAN markets).
Strategic Decision Framework
| Your Situation | Recommended Pathway |
|---|---|
| Novel device, no clear FDA predicate | MFDS first (no predicate barrier) |
| Existing CE Mark + FDA 510(k) cleared | Parallel pathway — both at once |
| Tight budget, need fast revenue | FDA 510(k) (larger market, faster ROI) |
| Korean clinical partnership in place | MFDS first (leverage local relationships) |
| AI/ML SaMD | Parallel; MFDS may clear faster |
| Class III device | Both pathways simultaneously (high clinical evidence burden) |
Parallel Submission Strategy
For most Class II devices, the recommended approach is parallel submission:
- Month 0: Initiate FDA 510(k) prep AND begin Korean STED preparation
- Month 1: Identify FDA predicate; map KGMP gap analysis
- Month 2–3: File 510(k); schedule KGMP inspection
- Month 4–6: FDA review in progress; complete KGMP
- Month 5–6: File MFDS registration with KGMP in hand
- Month 7–9: Both markets clear
This reduces total time-to-revenue by 4–6 months versus sequential submission.
Common Misconceptions
❌ "MFDS just accepts our FDA 510(k) clearance" — Incorrect. MFDS requires a separate technical dossier in Korean STED format with Korea-specific elements.
❌ "KGMP is the same as ISO 13485" — Incorrect. KGMP is harmonized with ISO 13485:2016 but adds Korea-specific requirements around design history file structure, change control documentation, and post-market obligations.
❌ "FDA 510(k) clearance is faster than MFDS" — Misleading. FDA's median 177-day decision time includes holds; MFDS's 60–90 day clock is more predictable for clean submissions.
Frequently Asked Questions
Q: Can our FDA 510(k) Clinical Performance Testing be reused for MFDS?
A: Largely yes. Performance testing per IEC/ISO standards is recognized by both. Reformat the test report to map Korean Medical Device Standard codes, and add a 1–2 page Korea-context discussion.
Q: Does MFDS approval help with FDA submissions?
A: Not directly as substantial equivalence, but MFDS clearance demonstrates regulatory rigor and is positively viewed by FDA reviewers as supplementary evidence in De Novo applications.
Q: Which is cheaper end-to-end?
A: For foreign manufacturers, total program costs are roughly comparable ($30K–$100K). FDA's higher user fees are offset by MFDS's KGMP cost and Korean translation requirements.
Q: We have ISO 13485 — does that satisfy KGMP?
A: No, but it accelerates KGMP preparation significantly. Most ISO 13485 elements map to KGMP; the gap is typically 6–8 weeks of additional documentation work.
How Leanabl Helps
- Regulatory Pathway Strategy — choose between MFDS-first, FDA-first, or parallel
- Korea Medical Device Registration — end-to-end MFDS submission
- Technical File Gap Analysis — assess EU/FDA file readiness for MFDS reformatting
Contact Leanabl for a pathway strategy session.
Last updated: 2026-05-15.
Have a regulatory question?
Talk to a Korea regulatory specialist about your device, your timeline, or your next submission.
Talk to a specialist
